LIBTAYO (Lib-TIE-oh) is a prescription medicine used to treat adults with a type of lung cancer called non–small cell lung cancer (NSCLC).
LIBTAYO may be right for adults with advanced NSCLC who have tumors that do not have an abnormal “EGFR,” “ALK,” or “ROS1” gene, and whose NSCLC:
And LIBTAYO may be used as your first treatment alone if your tumor tests positive for
high “PD-L1” or in combination with chemotherapy that contains a platinum medicine.
ALK=anaplastic lymphoma kinase; EGFR=epidermal growth factor receptor; PD-L1=programmed death ligand 1; ROS1=ROS proto-oncogene 1, receptor tyrosine kinase.